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Object. Transsphenoidal adenomectomy with resection of a defined pituitary adenoma has been the treatment of 
choice for CD for the last 30 years. Surgical resection, however, may not always result in long-term remission of CD. 
This is particularly important in light of the high risk of morbidity and mortality in patients in the unsuccessfully treat­
ed cushingoid state. As such, it is interesting to identify prognostic factors that may predict the likelihood of long-term 
remission.
Methods. The authors review their series of 174 patients who have undergone transsphenoidal procedures for CD 
over a period of 20 years with minimum follow-up periods of 5 years. Selection of these patients was based on clini­
cal, imaging, and laboratory criteria that included serum cortisol levels, loss of diurnal variation in serum cortisol lev­
els, urinary free cortisol concentration, and results of a dexamethasone suppression test, petrosal sinus sampling, and 
corticotroph-releasing hormone stimulation tests as indicated. All patients who met the biochemical criteria underwent 
transsphenoidal microsurgery.
The authors found an overall rate of remission of 74% at 5 years postoperatively. Patients in whom morning serum 
cortisol concentrations were lower than 3 jjLg/dl (83 nmol/L) on postoperative Day 3, following an overnight dexameth­
asone suppression test, had a 93% chance of remission at the 5-year follow-up examination. Patients with cortisol con­
centrations higher than this level uniformly failed to achieve long-term remission.
Conclusions. Transsphenoidal microsurgery is an effective means of control for patients with adrenocorticotrophic 
hormone-producing microadenomas. Clinical outcome correlated well with the size of the tumor, as measured on pre­
operative imaging studies, and with postoperative morning cortisol levels following an overnight dexamethasone sup­
pression test. Postoperative cortisol levels can be used as a useful prognostic indicator of the likelihood of future recur­
rence following transsphenoidal adenomectomy in CD.
Key  Words • Cushing disease • pituitary tumor • transsphenoidal approach • 
cortisol • outcome • survival
ush in g  disease is caused by the excessive secretion 
I  of ACTH from a pituitary adenoma. Lack of treat­
ment in cases of CD leads to complications from the 
resulting hypercortisolism including habitus changes, im ­
munosuppression, impaired wound healing, diabetes, hy­
pertension, left ventricular hypertrophy, and psychiatric ef­
fects. Patients with untreated CD survive a median of 5 
years according to data in the literature.
Treatment options for CD include neurosurgical inter­
vention, adrenalectomy, drug therapy, and radiosurgery. 
Since the early 1970s, TSA has been the preferred mode of 
treatment for CD.
Abbreviations used in this paper: ACTH = adrenocorticotropic 
hormone; CD = Cushing disease; CI = confidence interval; CRH = 
corticotropin-releasing hormone; CSF = cerebrospinal fluid; CT = 
computerized tomography; IPS = inferior petrosal sinus; MR = 
magnetic resonance; TSA = transsphenoidal adenomectomy; UFC = 
urinary free cortisol.
Despite advances in neurosurgical treatment of CD, suc­
cessful therapy remains a significant challenge. The overall 
published rate of remission following transsphenoidal mi­
crosurgery has been reported to be in the range of 70 to 
90%.4'6J'I’'I<U'U-U4 Significant prognostic factors associated 
with the success of surgery have included the size and inva­
siveness of the tumor.
Because of the significant rate of recurrence or persis­
tence of the disease and the attendant morbidity, it is of in­
terest to determine factors that may correlate with long-term 
outcomes following surgical intervention. Patients in whom 
failure of TSA is likely may, therefore, be considered can­
didates for repeated pituitary surgery, adrenalectomy, drug 
therapy, radiotherapy, or radiosurgical treatment. Parame­
ters including postoperative cortisol level,35 24-hour urine 
cortisol concentration,1 absence of a cortisol response to 
CRH,3 37 and the need for long-term glucocorticoid substitu­
tion3 have been described as useful prognostic indicators.
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Demographics o f patients who underwent 
transsphenoidal craniotomy for CD
TABLE 1
Factor No. of Patients
patients enrolled from 1973 to 1993 174
patients w/ 5-year follow up 152
lost to follow up 10
no. o f deaths’1' 4
nondiagnostic surgical explorations 12









* Four patients died: three o f coronary disease and one o f stroke.
The purpose of the present study is to review our series 
of patients harboring ACTH-secreting pituitary adenomas, 
who were treated with transsphenoidal surgery in view of 
5-year remission rates and complications. In particular, 
we have investigated postoperative morning cortisol levels 
measured after an overnight low-dose dexamethasone sup­
pression test to predict outcome following TSA.
C lin ic a l  M a t e r ia l  a n d  M e t h o d s
Patient Population
Data from the clinical records of all patients with ACTH- 
secreting adenomas who presented to the senior author 
(M.H.W.) from 1973 to 1993 were analyzed. The total se­
ries consisted of 174 patients. This cohort was chosen to al­
low a minimum long-term follow-up period of 5 years. Ten 
patients were lost to follow up and four patients died with­
in the follow-up period. In 12 patients the surgical explora­
tions were nondiagnostic. A subset of 152 patients with CD 
confirmed by surgical exploration completed the 5-year fol­
low up or died within the follow-up period. These patients 
form the study population. The demographics of these pa­
tients are summarized in Table 1.
A diagnosis of CD was based on the following criteria: 
loss of diurnal variation in serum cortisol levels; elevated 
concentration of 24-hour UFC; serum level of ACTH at the 
upper limit of normal or slighdy elevated; and failure to 
suppress the serum cortisol level after a low-level (2-mg) 
dexamethasone test. High-level dexamethasone suppres­
sion was seen in most cases, although in several 16 mg 
of dexamethasone was required. Abnormal findings of CT, 
MR imaging, and/or IPS and cavernous sampling studies 
were also used as criteria for exploration. In 22 cases, MR 
imaging, CT scanning, and IPS sampling yielded nondiag­
nostic findings and the patients underwent surgical explo­
ration on the basis o f abnormal biochemical findings alone. 
Imaging studies were performed in all patients in this series. 
No tumor could be identified on imaging studies in 42 pa­
tients. During surgical exploration of 162 patients we found 
microadenomas in 133 patients (82%) and macroadenomas 
in 29 patients (18%).
Microsurgical TSAs were performed via the sublabial 
approach in all patients, as previously described.10 In 12 pa­
tients no tumor was found during exploration and hemihy- 
pophysectomy was then performed. Exploration consisted 
of three vertical incisions in the gland and a midlevel hori­
zontal incision; this dissected the gland into eight segments 
for exploration. In the event that no tumor was found, we 
performed hemihypophysectomy, which consisted of resec­
tion of the lateral lobe on one side and the inferior segment 
of the midline mucoid wedge. In all patients in whom the 
arachnoid membrane was preserved, dehydrated ethanol 
was instilled in the tumor bed to treat potential microscop­
ic rests o f tumor cells. In patients in whom perforation of 
the arachnoid and egress of CSF was encountered, no alco­
hol was used. In these patients, we performed grafting by 
using autologous adipose tissue and/or fascia lata followed 
by lumbar puncture with dural fenestration.
Postoperative Management and Follow-Up Protocol
In the perioperative period, patients were treated accord­
ing to our standard protocol. On the 1st postoperative day, 
they were intravenously given 50 mg of hydrocortisone in 
the morning and 25 mg in the evening. On the 2nd day, they 
were given 50 mg of hydrocortisone in the morning and 1 
mg of dexamethasone in the evening at 10 p.m. Blood was 
withdrawn from the patient at 8 a.m. on the 3rd postop­
erative morning and a fasting serum cortisol level was 
measured and recorded. Following this procedure, hydro­
cortisone replacement was resumed. Corticoid medications 
were then tapered as tolerated by the patient. This general­
ly took 2 weeks to 1 year.
During the immediate postoperative period, the patients 
were carefully observed for diabetes insipidus or syndrome 
of inappropriate secretion of antidiuretic hormone. Nasal 
packings were removed on the 2nd postoperative day 
and patients were discharged on the 3rd or 4th postopera­
tive day.
An initial routine follow-up clinical evaluation was ob­
tained 6 weeks postoperatively and thereafter at 6-month 
intervals. At these visits, fasting cortisol levels were ob­
tained at 8 a.m. and 4 p.m. If patients demonstrated normal 
8 a.m. and 4 p.m. serum cortisol levels with normal diurnal 
variation, they were not required to undergo a repeated 24- 
hour test o f UFC. If the morning and late afternoon cortisol 
levels did not demonstrate a normal diurnal variation, how­
ever, a 24-hour UFC test was performed to confirm normal 
cortisol secretion. In the later years of the study, all patients 
underwent 24-hour UFC tests at least once postoperatively, 
even if normal diurnal variation was present. Patients sus­
pected of disease recurrence (loss of normal diurnal varia­
tion, elevated serum cortisol level, or elevated 24-hour UFC 
concentration) underwent a full endocrinological workup.
Statistical Analysis
Life tables were assembled to calculate 5-year disease- 
free survivals. Confidence intervals were calculated using 
the Greenwood method. Contingency tables were analyzed 
using the Fisher exact test as implemented in the algorithm 
of Mehta and Patel.21 Other statistical analyses were con­
ducted with the aid of a commercially available software 
package (Statistica ‘98; StatSoft, Inc., Tulsa, OK).
Surgical Technique
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T A B L E  2
Overall short-term outcomes for patients who underwent 
transsphenoidal craniotomy for ACTH-secreting tumors 
segregated by initial postoperative cortisol levels 
and surgical findings*





Group I 128 123 5
Group II 14 9 5
Group III 20 1 19
negative 12 NA NA
exploration
total 174 133 29
* NA = not applicable.
R e s u lt s
Role o f IPS Sampling
Inferior petrosal sinus sampling was used in 20 patients, 
in whom no evidence of tumor had been identified on imag­
ing studies.
In the 18 patients in whom the results of the IPS sampling 
were positive, all were found to have an adenoma on explo­
ration. In five of these patients, however, a higher ACTH 
level was found contralateral to the side where the adenoma 
was found. These results are consistent with and confirm 
the results o f previous investigators.18-539
Initial Response to Surgery
As shown in Table 2, patients' initial outcomes were 
categorized into three groups based on serum cortisol lev­
els obtained on postoperative Day 3 following a low-dose 
overnight dexamethasone suppression test. Group I con­
tained patients with cortisol levels lower than 3 |xg/dl (<  83 
nmol/L), Group II contained patients with low-to-normal 
postoperative ranges of cortisol (3-8 |xg/dl), and Group III 
contained patients in whom the cortisol level (>  8 |xg/dl) 
clearly indicated that surgery had failed.
Of the 162 patients in whom surgery revealed tumors, 
128 (79%) had morning cortisol levels lower than 3 |xg/dl 
on postoperative Day 3 following the low-dose dexametha­
sone suppression test. The size of the tumor was a highly 
significant factor in the likelihood of biochemical success. 
Although 123 (92%) of 133 patients with microadenomas 
had immediate postoperative morning cortisol levels below
3 |xg/dl, only five (17%) of 29 patients with macroadeno­
mas had immediate postoperative cortisol levels lower than
3 |xg/dl (p <  0.0001). Fourteen patients had postoperative 
cortisol levels between 3 and 8 |xg/dl following the low- 
dose dexamethasone suppression test. Overall short-term 
outcomes are summarized in Table 2.
Complications From Surgery
Complications were rare in this series. In 72 patients, fat 
and/or fascia lata grafting was required. In no patient did a 
CSF leak requiring reoperation occur or meningitis devel­
op. Three patients did, however, sustain infections at graft 
donor sites. In all such instances, the isolated organism was 
Staphylococcus aureus. These results were largely judged
TABLE 3







(2142 patients) p Value*
CSF leak 0 24 0.16
grafts 72 733 0.88
meningitis 0 9 1.00
donor-site infection 3 14 0.19
* Probability values were calculated using the Fisher exact test.
not to be statistically significant when compared with the 
overall series of patients undergoing transsphenoidal micro­
surgery (Table 3). Similarly, no statistical significance was 
seen for the incidence of fat graft requirements. There were 
no perioperative deaths or complications leading to new 
neurological deficits in this series. Although an intensive 
postoperative assessment of the endocrinological axis was 
not performed on a routine basis following surgery, no pa­
tient to our knowledge has required treatment for a new 
endocrinological deficit following selective TSA. Interest­
ingly, no patient who underwent the hemihypophysectomy 
described earlier experienced pituitary insufficiency as a 
consequence of this procedure.
Long-Term Results
Overall Sunival. A 5-year follow-up period was obtained 
in 152 patients (87%). Ten patients were lost to follow up 
before the 5-year period, but these patients were included in 
the actuarial analysis to comprise a total series of 162 pa­
tients. Four patients died during the accrual period, three of 
coronary artery disease and one of stroke (Table 4). Twelve 
additional patients, in whom surgical explorations were not 
diagnostic, were not included in the analysis. These data al­
low a calculation of an actuarial 5-year life survival rate of 
97.3% (95% CI 94.8-99.9%).
Disease Remission. For all 162 patients in whom surgery 
uncovered a tumor, 118 (72.8%) experienced remission 
from hypercortisolism (normal morning and late afternoon 
cortisol levels with diumal variation or normal 24-hour lev­
els of UFC) at 5 years (95% CI 87.9-57.7%). A Kap- 
lan-M eier curve demonstrating disease-free remission in 
all patients in whom surgery revealed a tumor is presented 
in Fig. 1.
Initial postoperative cortisol levels correlated well with 
the likelihood of long-term remission. For the 121 patients 
in Group I who had completed a 5-year follow-up period, 
113 had normal fasting 8 a.m. and 4 p.m. serum cortisol lev-
T A B L E  4











1 heart disease 5.4 49 no
2 heart disease 8.2 40 no
3 heart disease 2.3 58 ves
4 stroke 2.8 50 yes
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Fig. 1. Kaplan-Meier curve demonstrating actuarial recurrence-free survival for all patients in this series in whom sur­
gical explorations revealed a tumor.
els with diurnal variation or normal 24-hour UFC levels at 
the end of the 5-year follow up, yielding a long-term actu­
arial remission rate of 93% (95% CI 88.7-97.3%).
O f the 14 patients in the initial cohort of Group II, 11 
completed the 5-year follow up. None of these patients con­
tinued to experience remission at the end of 5 years. For 
these patients, the median time to treatment failure was 18 
months. A Kaplan-M eier graph of recurrence-free survival 
is presented in Fig. 2.
After we separated out the patients with microadenomas 
from Group 1 ,112 of 116 patients continued to have disease 
remission at 5 years postoperatively, yielding a long-term 
actuarial remission rate of 96.5% (95% CI 93.2-99.8%). In 
the patients with macroadenomas, continued disease remis­
sion was found in only one of five at 5 years. For patients 
in Group I in whom disease recurred, the median time to re­
currence was 27 months with a range of 6 to 48 months.
No patient who ceased taking corticoid medications less 
than 6 weeks postoperatively achieved disease remission. 
All these patients had postoperative Day 3 morning cortisol 
levels greater than 5 (xg/dl (138 nmol/L).
Characteristics and Management o f  Disease Recurrence
In patients with initially low cortisol levels, recurrences 
of disease were observed 6 months to 4 years postopera­
tively. O f the four original macroadenomas that recurred, 
recurrent or residual tumor was found on MR imaging stud­
ies in all cases. These tumors were reexplored; however, re­
mission was not reestablished in any of these patients by the 
second surgery. Of the four original microadenomas that re­
curred, one was identified as recurrent tumor on imaging. 
This tumor was reexplored and remission was again estab­
lished by the second surgery. Failed treatments included 
three adrenalectomies accompanied by application of radi­
ation to the sella turcica, one application of radiation to the 
sella plus a regimen of ketoconazole, and one regimen of 
ketoconazole alone.
Treatment o f Patients With Failed Explorations
For the 12 patients in whom surgical exploration was
nondiagnostic, none achieved disease remission postopera­
tively from performance of a hemihypophysectomy alone. 
Eight of the 12 patients subsequently underwent adrenalec­
tomy with fractionated external beam radiotherapy directed 
to the sella turcica. There were no deaths in this subgroup 
and all patients achieved remission of their CDs. Seven of 
eight patients did have panhypopituitarism, however. The 
remaining four patients underwent total hypophysectomies, 
which were performed early in this series. Three of these 
patients experienced total hypopituitarism as a result of the 
second procedure, and one patient experienced persistent 
hypercortisolemia and was treated with radiation directed to 
the pituitary, subsequent to an attempted total hypophysec- 
tomy. There were no patients in whom Nelson syndrome 
developed in this series.
D is c u s s io n
Surgical Management o f  CD
Extensive experience over the last quarter of a century 
has demonstrated the high safety and efficacy of transsphe­
noidal surgery in the treatment of CD.5-’83436 Improvements 
in surgical technique since the advent of the operating mi­
croscope have improved, to a significant extent, outcomes 
following pituitary surgery.
The present study confirms the efficacy of transsphe­
noidal microsurgical resection for CD and identifies factors 
that correlate with outcome at a standardized end point o f 5 
years.
Despite excellent results in the majority of patients, sur­
gical therapy will fail in a significant minority. In many 
of these patients, treatment failures clearly manifest them­
selves only months or years following the initial surgical in­
tervention. The complications of a continued cushingoid 
state are well known, and include diabetes, changes in habi­
tus, and depression. It is useful, therefore, to have the means 
to identify patients who are at higher risk of disease recur­
rence following transsphenoidal surgery. Patients who are 
at clear risk for disease recurrence may potentially benefit 
from a closer follow up and early adjuvant therapy.
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In accordance with previously published data, factors 
associated with poorer outcomes have been identified to in­
clude tumor size larger than 1 cm in diameter and tumor in­
vasiveness.2'4'15
In the present series, the initial remission rate, as oper­
ationally defined by dexamethasone-suppressed serum cor­
tisol levels of 3 (xg/dl on postoperative Day 3, was 80%, 
which is comparable to the initial response rates published 
by other groups.5-1928 ,4 ,5 The overall 5-year survival rate of 
greater than 97% is substantially better in comparison with 
a historical control series in which the 5-year mortality rate 
was calculated to be as high as 50%, and is similar to the re­
cent results of Swearingen, et al.33
Prognostic Factors for Recurrence and the Role o f  
Serum Cortisol
Previous investigators have used a variety of indices to 
determine the likelihood of disease recurrence. Each of 
these indices has certain advantages and disadvantages in 
the clinical setting. Arnott and coworkers1 examined the 
predictive value of the 24-hour urine cortisol level in 26 pa­
tients 1 to 4 weeks following pituitary surgery. They found 
that, in all patients with suppressed 24-hour urine cortisol 
levels, long-term remissions could be expected. Unfortu­
nately, the mean follow-up period in that study was less 
than 2 years.
Several investigators have analyzed the role of postop­
erative cortisol levels as an early prognostic indicator of 
surgical success. Trainer and coworkers35 examined the 
nonsuppressed postoperative morning cortisol level in 48 
patients who had undergone TSA and were followed for a 
mean of 40 months. They found that no patient with a post­
operative serum cortisol level o f 50 nmol/L (1.8 (xg/dl) or 
less had recurrence of CD. Recent data, however, have con­
tradicted the main conclusion of this publication.38 Fahl- 
busch and coworkers12 have recommended that postop­
erative ACTH levels be considered in the evaluation of 
postoperative patients. A parameter that is related to postop­
erative cortisol suppression is the need for replacement with 
exogenous corticoid medications. In a multicenter retro­
spective study, Bochicchio, et al.,3 found the need for post­
operative cortisol replacement to be a factor predictive of 
long-term disease remission. Vignati and associates37 exam­
ined the role o f the postoperative CRH stimulation test in 30 
patients who were followed between 9 months and 10 years 
after surgery. Continued suppression of a normal response 
was considered predictive of remission.
Our protocol for postoperative evaluation has concentrat­
ed on the use of early postoperative dexamethasone-sup- 
pressed morning serum cortisol levels. We have found this 
test to be easily obtainable and a useful predictor o f long­
term disease-free survival. In this group, 93% o f patients 
with a postoperative cortisol level lower than 3 (xg/dl ex­
perienced remission at the 5-year follow up. Postoperative 
morning cortisol levels have the advantage of being widely 
available and simple to obtain in comparison with other pre­
dictive indices.
Nugent and coworkers24 and Pavlatos, et al.,2'3 initially de­
scribed the low-dose overnight dexamethasone suppression 
test for the rapid diagnosis o f Cushing syndrome. When 
used in the diagnostic setting, there are relatively high false- 
positive and false-negative rates,913-32 especially when used
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Fig. 2. Kaplan-Meier graph comparing recurrence-free survival 
for patients in Group I (solid line) and Group II (broken line).
in patients in whom concurrent illness may lead to a reduc­
tion in the suppressibility of the adrenal axis. The results of 
the present study suggest, by contrast, that in the postop­
erative setting the findings of low morning cortisol levels 
after an overnight low-dose dexamethasone suppression 
test has a high sensitivity for patients who will experience a 
long remission following transsphenoidal surgery, and a 
high specificity for those in whom the intervention will fail 
within a 5-year follow-up period. In contrast to the diagnos­
tic setting, all the patients included in this series had proven 
hypercortisolism due to pituitary disease rather than to other 
disease states such as depression or chronic illness. Patients 
with ACTH-secreting pituitary adenomas have chronically 
suppressed pituitary axes and, in the setting of a success­
ful removal of tumor, would be expected to have below 
normal levels o f cortisol after a low-dose dexamethasone 
challenge. The remaining nonsuppressed cortisol function 
would be due to residual ACTH-secreting tissue in this 
highly selected population. This hypothesis was largely 
borne out by the observations of the present study. Low 
plasma cortisol levels were a good, but not a completely re­
liable indicator of long-term remission, with 5% of patients 
experiencing recurrence of their disease within a 5-year pe­
riod. Dexamethasone-suppressed postoperative cortisol lev­
els higher than 3 (xg/dl, however, were a reliable indicator 
of long-term surgical failure.
Similar results were obtained by Imaki, et al.,17 in their 
series of 30 patients who had undergone successful initial 
procedures. One of 25 patients in whom the dexameth­
asone-suppressed plasma cortisol level was lower than 2 
(xg/dl experienced recurrence of disease, whereas three of 
five patients with cortisol levels higher than 2 (xg/dl experi­
enced recurrence during a median follow-up period of 87.6 
months. Recently, Yap and colleagues38 reported their expe­
rience in 66 patients who initially had undetectable nonsup­
pressed serum cortisol levels. In their study the authors not­
ed an 11.5% incidence of disease recurrence was noted over 
a median 36-month follow-up period.
We have routinely used perioperative cortisol replace­
ment to avoid an acute symptomatic addisonian state in 
the postoperative period. The morning cortisol concentra­
tion obtained in the early postoperative course following an
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overnight low-dose dexamethasone suppression test can be 
used to determine the residual production while reducing 
the severity of postoperative symptoms. We do recognize, 
however, that there are groups that do not routinely give pa­
tients immediate postoperative cortisol replacement, which 
may affect the ability to compare our results directly with 
those of others. In a recent report30 the authors suggested 
that postoperative cortisol replacement is not routinely in­
dicated following transsphenoidal surgery on the 1st post­
operative day. It is unclear, however, whether this rec­
ommendation can be continued to the 3rd postoperative 
day, the time at which the cortisol sampling took place in 
our protocol. Certainly, even with postoperative cortisol 
replacement, many of our patients did have symptoms of 
cortisol withdrawal including nausea and headaches. On the 
basis o f the present results, it does not appear that our use 
of dexamethasone-suppressed values of cortisol adversely 
affect the sensitivity and specificity of postoperative corti­
sol testing in comparison with the nonsuppressed values ob­
tained by other groups.83538 W hether routine postoperative 
cortisol replacement should be used, however, continues to 
be unclear, and further research is warranted in this area.
Treatment o f  Patients in Whom the Initial Surgical 
Exploration has Failed
Our results show that no patient with a postoperative cor­
tisol level greater than 3 (xg/dl achieved long-term remis­
sion of their disease. We believe that these patients should 
be considered as likely treatment failures and should be 
monitored vigilantly. Surgical reexploration should be con­
sidered,14-2735 as should adjuvant therapy. Adjuvant therapy 
may include drug therapy,31 adrenalectomy,20 fractionated 
external beam radiation,11 or stereotactic radiosurgery.22-29 
Such measures are reasonable in the management of uncon­
trolled CD with its high incidence of morbidity and demon­
strated 5-year mortality rate.
C o n c lu s io n s
We found the early postoperative morning cortisol level 
to be a very good, but not absolute prognostic indicator for 
patients treated by transsphenoidal craniotomy for CD. Pa­
tients with postoperative serum cortisol levels below nor­
mal (<  3 (xg/dl) had a 93% chance of disease remission at 
the 5-year follow up. No patient with a normal postopera­
tive cortisol level (3-8 (xg/dl), however, experienced dis­
ease remission. These patients should be informed of their 
poor prognosis for remission and an appropriate interven­
tion should be taken.
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